Physician profile
David Wichman
NPI 1760695290
$612,629.98
in general payments reported to CMS, 2019-2025
24 companies · $145K in 2025
The $145K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $35K · 2021: $77K · 2022: $30K · 2023: $165K · 2024: $73K · 2025: $145K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $272K · Consulting Fee: $51K · Honoraria: $26K · Travel and Lodging: $23K · Food and Beverage: $11K · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $272,265.00 |
| Consulting Fee | $51,250.00 |
| Honoraria | $25,575.00 |
| Travel and Lodging | $22,557.63 |
| Food and Beverage | $11,073.88 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390,511.08 | 2021-2025 | Vraylar |
| Allergan, INC. | $86,040.63 | 2019-2020 | |
| Axsome Therapeutics, INC. | $81,496.22 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $26,435.35 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $17,779.65 | 2019-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $4,402.37 | 2019-2025 | Trintellix |
| Brainsway USA INC | $3,120.14 | 2025 | Deep Tms System |
| Idorsia Pharmaceuticals US INC | $1,190.00 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $211.42 | 2022-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $168.39 | 2022-2025 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $166.72 | 2021-2024 | Xywav |
| Corium, LLC | $156.80 | 2022-2024 | Azstarys |
| Alkermes, INC. | $148.72 | 2024-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $142.57 | 2022-2025 | Spravato |
| Lundbeck LLC | $115.30 | 2020-2024 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $105.29 | 2021-2024 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $100.77 | 2022-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $85.08 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $66.73 | 2025 | Fanapt |
| Harmony Biosciences LLC | $66.09 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $40.38 | 2020-2021 | |
| Tris Pharma INC | $38.26 | 2021-2022 | |
| Eisai INC. | $27.24 | 2020-2021 | |
| Neos Therapeutics, LP | $14.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wichman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.